Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × MK 2206 × Myeloid × Clear all
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
LymphoidMyeloidOther hematologic neoplasmSarcoma

Myeloproliferative Syndrome, Transient, Pdgfra-Associated Chronic Eosinophilic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Burkitt Lymphoma, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma